JP Morgan raises Centene price target to $60
JP Morgan analyst John Stansel maintains a Neutral rating on Centene and raises the price target to $60 from $52, adjusting the valuation outlook.
*this image is generated using AI for illustrative purposes only.
JP Morgan analyst John Stansel has maintained a Neutral rating on Centene (NYSE: CNC) and raised the price target to $60 from $52. The adjustment reflects a revised valuation outlook for the healthcare company.
Rating and Price Target
The firm's stance on Centene remains Neutral, indicating a balanced risk-reward profile. The increase in the price target suggests a more optimistic view of the stock's potential upside compared to the previous estimate.
| Metric | Value |
|---|---|
| Rating | Neutral |
| Previous Price Target | $52 |
| New Price Target | $60 |
Centene operates as a multi-national healthcare company focused on managed care. The updated price target provides a new benchmark for investors tracking the stock's performance.
What specific factors drove the revision in Centene's valuation outlook?
How might Centene's managed care segment perform amid changing healthcare policies?
What are the potential risks that could justify the Neutral rating despite the raised price target?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
